This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: I24 (Other acute ischemic heart diseases) | Special Copayment Reduction: V192 (heart disease special copayment reduction: 5% copayment for up to 30 days from the registration date) |
| B. Synonyms | Dressler syndrome, acute coronary thrombosis (not resulting in infarction), unstable angina (in some classifications), Dressler syndrome, postinfarction syndrome |
| C. Adult onset | Acute ischemia-related syndromes such as Dressler syndrome, occurring within weeks after myocardial infarction or cardiac surgery, and coronary thrombosis not resulting in infarction; presents mainly in adults from middle age onward. |
| 1. History | History from William Dressler's first description of postinfarction syndrome in 1956 to the modern ICD classification system |
| 2. Causes | Various mechanisms, including immune-mediated pericarditis (Dressler), coronary thrombosis, vasospasm, and stunned myocardium |
| 3. Genetics | HLA genotypes and genetic variants related to autoimmune predisposition are involved in susceptibility to Dressler syndrome |
| 4. General epidemiology | Incidence of Dressler syndrome about 3–4% before reperfusion therapy, now <1%; I24 as a whole is a rare diagnostic group but clinically important |
| 5. Pathophysiology | Mechanism of pericardial and pleural inflammation via autoantibody formation, exposure of myocardial autoantigens, and the complement activation pathway |
| 6. Symptoms | Fever, pleuritic chest pain, and dyspnea recurring weeks after infarction; the characteristic triad of Dressler syndrome |
| 7. Signs | Pericardial friction rub, pleural friction rub, fever, pericardial effusion, and pleural effusion appear as characteristic physical findings |
| 8. Screening | Regular clinical evaluation, electrocardiography, inflammatory markers, and chest radiography after infarction are the main screening tools |
| 9. Diagnosis | Definitive diagnosis and differential diagnosis by echocardiography, cardiac MRI, coronary angiography, and autoantibody testing |
| 10. Treatment | Aspirin, NSAIDs, and colchicine are first-line treatment for Dressler syndrome; corticosteroids are used second-line in recurrent or refractory cases |
| 11. Prognosis | Dressler syndrome generally has a benign course; it can recur, but attention is needed for rare complications such as cardiac tamponade |
| 12. Prevention | Early reperfusion therapy, continued aspirin administration, and prophylactic colchicine use are effective in preventing Dressler syndrome |
| 13. References | Dressler W. A post-myocardial-infarction syndrome: preliminary report of a complication resembling idiopathic, recurrent, benign pericarditis … and 9 other papers |
The history of other acute ischemic heart diseases in the ICD I24 category unfolds mainly around the discovery of Dressler syndrome and the evolution of its concept. In 1956 the American internist William Dressler first systematically described a distinctive clinical syndrome of fever, pleuritic chest pain, and pericarditis occurring several weeks after myocardial infarction and named it "post-myocardial infarction syndrome." He predicted that this syndrome was caused by an immune response to autoantigens after infarction, which was later supported by autoimmune mechanisms.
In the 1950s–1960s, Dressler syndrome was observed in 3–5% of patients with myocardial infarction, and at that time corticosteroids were used as the main treatment. However, as concerns were raised that long-term corticosteroid use could impair myocardial healing after infarction, debate over the treatment paradigm began.
With the spread of reperfusion therapy in the 1980s, the incidence of Dressler syndrome decreased dramatically. The main reason is presumed to be the reduction in infarct size and decreased exposure of myocardial autoantigens in the blood due to thrombolytic therapy and primary percutaneous coronary intervention (PCI). The incidence of Dressler syndrome is currently reported to have decreased to less than 1%.
In the ICD-10 classification system, I24 consists of a heterogeneous group of diseases including coronary thrombosis not resulting in myocardial infarction (I24.0), Dressler syndrome (I24.1), other forms of acute ischemic heart disease (I24.8), and acute ischemic heart disease, unspecified (I24.9). Since the 2000s, with the establishment of new acute ischemia-related concepts such as stunned myocardium, hibernating myocardium, and Takotsubo syndrome, the clinical meaning of the I24 category has become even more complex.
Recently, the role of colchicine in the treatment of postinfarction pericarditis, including Dressler syndrome, has drawn attention. Several randomized controlled studies, including the COPE study (2005) and the ICAP study (2013), have demonstrated that colchicine is effective in the treatment and prevention of acute and recurrent pericarditis. The 2025 ESC guidelines present combination therapy with aspirin or NSAIDs plus colchicine as the first-line recommendation for all forms of pericardial disease.
The diseases included in ICD I24 have various causative mechanisms. The main cause of Dressler syndrome (I24.1) is an autoimmune response to autoantigens released from myocardial tissue after myocardial infarction or cardiac surgery. Myocardial proteins such as myosin, actin, and troponin are released into the bloodstream from infarcted myocardial cells and induce autoantibody formation. These autoantibodies and autoantigens react in the pericardium and pleura, triggering an inflammatory response. It can also occur by the same mechanism after previous cardiac surgery (postpericardiotomy syndrome) or chest trauma.
The cause of acute coronary thrombosis not resulting in infarction (I24.0) is thrombus formation due to rupture or erosion of atherosclerotic plaque, in cases where the thrombus lyses spontaneously and does not actually progress to myocardial necrosis (myocardial infarction). Coronary vasospasm, endothelial dysfunction, and platelet hyperactivation also cause thrombus formation. Cocaine use, severe emotional stress (Takotsubo-like mechanism), and excessive catecholamine secretion can also promote vasospasm and thrombus formation.
Other forms of acute ischemic heart disease (I24.8) may include stunned myocardium and hibernating myocardium. Stunned myocardium is a condition in which myocardial function recovers with delay after transient ischemia, with ventricular dysfunction persisting for hours to days even after reperfusion. Oxidative stress, calcium overload, and contractile protein dysfunction are the main causative mechanisms. Hibernating myocardium is an adaptive response in which the myocardium protects itself by minimizing metabolism under chronic hypoperfusion, and function can recover with reperfusion.
Known risk factors for the development of Dressler syndrome include large myocardial infarction (autoantigen release increases in proportion to the degree of myocardial injury), not receiving anticoagulant therapy, a history of previous pericarditis, and a predisposition to immune abnormalities. Conversely, reduction of infarct size by early reperfusion therapy and long-term aspirin administration are understood to be the main factors suppressing the development of Dressler syndrome.
In diseases involving autoimmune mechanisms such as Dressler syndrome, HLA (human leukocyte antigen) genotype plays an important role in susceptibility. Because HLA molecules regulate autoimmune responses by presenting autoantigen peptides to T lymphocytes, carriers of certain HLA alleles may mount a more vigorous immune response to myocardial autoantigens. Some study results have reported that certain HLA-DR genotypes are associated with the development of postinfarction pericarditis, but large confirmatory studies are lacking.
Polymorphisms of the CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) gene, which is involved in regulating autoimmune responses, may also be associated with susceptibility to Dressler syndrome. Because CTLA-4 transmits inhibitory signals for T-cell activation, autoimmune responses may be stronger in patients with loss-of-function variants. Similarly, the W620 variant of the PTPN22 (protein tyrosine phosphatase non-receptor type 22) gene is associated with several autoimmune diseases, so a role in Dressler syndrome is suspected as well.
With regard to coronary thrombosis not resulting in infarction (I24.0), genetic variants related to thrombophilia are important. Factor V Leiden (FVL: G1691A), prothrombin G20210A, and MTHFR (methylenetetrahydrofolate reductase) C677T variants cause a hypercoagulable state and promote thrombus formation. Platelet receptor genes (polymorphisms of the GPIb-IX-V complex, the GPIIIa PlA2 allele) increase the tendency toward platelet aggregation and may be associated with thrombus formation without infarction.
In stunned myocardium and hibernating myocardium, genetic variants involved in an individual's mitochondrial function and tolerance to oxidative stress may affect the efficiency of myocardial protective mechanisms. The Val16Ala polymorphism of the SOD2 (superoxide dismutase 2, mitochondrial) gene is associated with the efficiency of mitochondrial oxidative stress handling and may affect myocardial protection in ischemia-reperfusion injury.
The epidemiology of the other acute ischemic heart disease (I24) category varies greatly by subcategory. The incidence of Dressler syndrome (I24.1) was reported in the 1960s–1970s, before reperfusion therapy became widespread, as 3–5% of patients with acute myocardial infarction. However, after thrombolytic therapy and primary PCI became standard treatment, the incidence decreased greatly to the level of 0.5–1.0%. Dressler syndrome has now become a rare complication in patients with myocardial infarction, but postpericardiotomy syndrome occurring after cardiac surgery is still reported in 20–30% of surgical patients.
Dressler syndrome occurs mainly in middle-aged and older adults and is reported slightly more frequently in men. Onset is most common between 1 and 8 weeks after infarction or surgery, and in some cases it occurs months later. Recurrence is possible after the first episode, and some cases follow the course of a recurrent syndrome.
The exact incidence of acute coronary thrombosis not resulting in infarction (I24.0) is difficult to determine. Because it includes cases among patients with acute coronary syndrome undergoing coronary angiography in whom thrombus is observed but there is no actual myocardial necrosis, incidence estimates differ depending on the conceptual definition. Vasospastic angina (variant angina, Prinzmetal angina) occurs in about 0.02% of the general population, and there are reports that it is relatively more common in East Asians than in Westerners.
In Korea, studies based on health insurance claims data estimate that the diagnostic frequency of the I24 code accounts for about 5–10% of all ischemic heart disease, but there is large variation depending on the accuracy of diagnostic classification and coding practices. Because a clear boundary with acute myocardial infarction is often clinically difficult to establish, uncertainty exists in epidemiological statistics.
The key to the pathogenesis of Dressler syndrome is an autoimmune response. In acute myocardial infarction, myocardium-specific proteins (myosin, troponin I/T, creatine kinase-MB, etc.) are released in large amounts from necrotic myocardial cells into the bloodstream. These proteins are normally shielded from the immune system ("immunologically privileged sites") and are exposed to the immune system for the first time due to cell membrane destruction from infarction. This induces antigen-specific T-cell activation and formation of anti-myocardial autoantibodies.
The resulting autoantibodies and autoreactive T cells cross-react with the mesothelial cells of the pericardium and pleura, causing immune complex-mediated inflammation. Activation of the complement system, mast cell degranulation, and infiltration of neutrophils and macrophages amplify the inflammatory response in the pericardium and pleura. In this process, inflammatory mediators such as prostaglandins, interleukin-1, and TNF-α are released, causing chest pain and fever.
The mechanism of coronary thrombosis not resulting in infarction (I24.0) is platelet aggregation and thrombus formation due to rupture or erosion of atherosclerotic plaque. When plaque ruptures, subendothelial collagen and tissue factor are exposed, triggering platelet activation and the coagulation cascade. Even if a thrombus forms to some extent, it does not progress to infarction if it is lysed by spontaneous fibrinolysis or drugs, or if the thrombus does not reach complete occlusion. Concurrent vasospasm further worsens the reduction in blood flow.
The mechanism of stunned myocardium is oxidative stress and calcium overload due to ischemia-reperfusion injury. On reperfusion, the resumption of oxygen supply generates large amounts of reactive oxygen species (ROS), causing lipid peroxidation of cell membranes, protein oxidation, and DNA damage. At the same time, excessive influx of calcium ions into cells causes contractile protein dysfunction and mitochondrial failure. This injury is reversible, and myocardial function recovers over time.
The characteristic symptoms of Dressler syndrome (I24.1) are the triad of fever, pleuritic chest pain, and dyspnea appearing 1–8 weeks after myocardial infarction. The chest pain is sharp and stabbing, relieved by sitting up and leaning forward and worsened by lying down, suggesting pleural or pericardial inflammation. Inspiration-related pain that worsens with inspiration (pleuritic chest pain) is characteristic. Fever is generally around 38–39℃, and general malaise, loss of appetite, and joint pain may accompany it.
In Dressler syndrome, when a large pericardial effusion forms, it can progress to cardiac tamponade, causing a sudden drop in blood pressure, worsening dyspnea, and decreased consciousness. In most cases, however, the pericardial effusion is moderate or smaller and hemodynamic stability is maintained. When pleural effusion is present, cough and dyspnea are prominent and a pleural friction rub is heard.
The symptoms of coronary thrombosis not resulting in infarction (I24.0) resemble those of acute coronary syndrome. The main symptom is pressure, heaviness, or tightness in the lower sternum or left chest occurring at rest or with mild activity, which may radiate to the left arm, jaw, neck, and back. It may be accompanied by sweating, nausea, vomiting, and dyspnea. When vasospasm is the main mechanism (Prinzmetal angina), symptoms characteristically occur at rest between midnight and early morning and tend to respond immediately to nitroglycerin.
In stunned myocardium, fatigue, dyspnea, and exercise intolerance may persist even after reperfusion, and heart failure symptoms sometimes appear transiently. In mild cases, symptoms may be absent or minimal, with ventricular dysfunction confirmed only on follow-up echocardiography.
The most characteristic auscultatory finding in Dressler syndrome is a pericardial friction rub, a scratching sound heard at the left sternal border. This rub is produced by friction between the two layers of the pericardium and is best heard at end-expiration with the patient sitting up and leaning forward. When pleural inflammation is present, a pleural friction rub is also heard. As the pericardial effusion increases, the rub may actually disappear, heart sounds diminish, and the cardiac silhouette enlarges.
Fever (38℃ or higher) is an essential sign of Dressler syndrome, and increased pulse rate and worsening of chest pain on inspiration are observed. With progression to cardiac tamponade, pulsus paradoxus (a decrease in systolic blood pressure of 10mmHg or more on inspiration), jugular venous distension, and muffled heart sounds appear (Beck's triad). With pleural effusion, dullness to percussion, decreased breath sounds, and a friction rub are observed. Abdominal findings such as hepatomegaly and ascites, signs of right heart failure, may appear in severe cases.
In coronary thrombosis not resulting in infarction (I24.0), there are no specific auscultatory findings, but during severe ischemia an S3 or S4 gallop rhythm may be heard transiently, and a functional mitral regurgitation murmur due to papillary muscle ischemia may be heard. Blood pressure may be normal or transiently elevated due to sympathetic activation. During severe vasospastic attacks, transient loss of consciousness (syncope) sometimes occurs.
To screen for Dressler syndrome, clinical evaluation is performed immediately if symptoms such as fever or recurrent chest pain appear within 1–8 weeks after myocardial infarction or cardiac surgery. Inflammatory markers—C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and white blood cell count (neutrophil predominance)—are used to confirm active inflammation. Elevated CRP supports the diagnosis of Dressler syndrome and is also used to monitor treatment response.
The 12-lead electrocardiogram may show concave (saddle-shaped) ST-segment elevation and PR-segment depression across all leads, which are characteristic findings of acute pericarditis. Differentiation from localized ST elevation due to reinfarction is important; pericarditis is characterized by the absence of reciprocal changes and by ST elevation distributed across multiple leads. PR-segment elevation in lead aVR is specific to pericarditis.
Plain chest radiography is useful for evaluating enlargement of the cardiac silhouette (pericardial effusion) and pleural effusion (increased pleural opacity). Pleural effusion may be left-sided or bilateral and is often accompanied by pericardial effusion. If the cardiac silhouette is markedly enlarged, it is confirmed immediately by echocardiography.
Measurement of troponin I/T and CK-MB is needed to determine whether myocarditis is present and to differentiate reinfarction. When myocarditis accompanies Dressler syndrome, troponin may be mildly elevated, but not as markedly as in reinfarction. It is important to track the trend of cardiac enzymes through repeated measurements.
The diagnosis of Dressler syndrome depends on comprehensive assessment of clinical symptoms and test findings. As diagnostic criteria, it is considered when two or more of the following are present: onset within 1–8 weeks after myocardial infarction or cardiac surgery, fever (38℃ or higher), pleuritic chest pain, pericardial or pleural friction rub, pericardial/pleural effusion, and elevated CRP.
Transthoracic echocardiography (TTE) is central to evaluating the presence and extent of pericardial effusion and whether cardiac tamponade is present. The distribution of pericardial effusion (localized vs. generalized), right ventricular diastolic collapse, and inferior vena cava distension with reduced inspiratory collapse are findings suggestive of cardiac tamponade. In addition, baseline ventricular function is evaluated to check for concomitant conditions such as stunned myocardium.
Cardiac magnetic resonance imaging (CMR) is excellent for evaluating the extent and degree of pericardial inflammation in the diagnosis of Dressler syndrome. T1 mapping and T2 mapping can quantitatively assess pericardial inflammation and edema, and late gadolinium enhancement (LGE) evaluates pericardial fibrosis and myocardial inflammation. CMR is also useful for determining whether myocarditis is present.
Coronary angiography (CAG) is essential for diagnosing coronary thrombosis not resulting in infarction (I24.0) and other acute ischemic heart diseases. Vasospasm can be diagnosed by ergonovine or acetylcholine provocation testing. Optical coherence tomography (OCT) or intravascular ultrasound (IVUS) is useful for evaluating plaque characteristics, presence of rupture, and thrombus composition. Anti-myocardial autoantibody testing (anti-myosin antibodies, etc.) supports the diagnosis of Dressler syndrome, but its clinical use is limited.
First-line treatment of Dressler syndrome (I24.1) is combination therapy with aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) plus colchicine. Aspirin (750–1000mg/day, in 3 divided doses) or ibuprofen (1800–3200mg/day) is used for 2–4 weeks, and at the same time colchicine (0.5mg twice/day, once/day if body weight <70kg) is given in combination for 3 months. Colchicine is also effective in preventing recurrence. The dose is gradually tapered as symptoms improve.
When there is no response to or a contraindication to aspirin and NSAIDs, or in recurrent Dressler syndrome, corticosteroids (prednisolone 0.2–0.5mg/kg/day) are used. However, it is recommended that they be avoided as much as possible early after infarction (within at least 1 month), because they can impair myocardial healing and increase the risk of post-infarction ventricular rupture. If cardiac tamponade develops, pericardiocentesis is performed immediately.
Treatment of coronary thrombosis not resulting in infarction (I24.0) is based on antithrombotic therapy equivalent to that for acute coronary syndrome. Dual antiplatelet therapy, anticoagulants, and coronary intervention if needed are performed. When vasospasm is the main mechanism (Prinzmetal angina), calcium channel blockers and nitrates are first-line treatment, and caution is needed with beta-blockers because they can worsen vasospasm.
Because stunned myocardium mostly recovers spontaneously over time, conservative treatment is the principle. In the acute phase, drugs that prevent ventricular remodeling, such as beta-blockers and ACE inhibitors, are used, and when heart failure symptoms are prominent, temporary use of inotropes (dobutamine, etc.) may be needed. Unnecessary inotrope use increases myocardial oxygen consumption and may be harmful to stunned myocardium, so it should be judged carefully.
Dressler syndrome is a disease with an overall benign course. With appropriate anti-inflammatory treatment, symptoms resolve completely within a few weeks in most patients. The risk of death is low, but rarely cardiac tamponade due to a large pericardial effusion can develop, progressing to an emergency requiring immediate management. Transition to constrictive pericarditis is very rare, but long-term follow-up is needed in recurrent or treatment-refractory cases.
Recurrence is reported to be experienced by about 20–30% of patients. Colchicine is effective in preventing recurrence, and the COPPS study (2010) demonstrated that colchicine reduced the risk of recurrence by 58% in pericardial effusion after pericardiotomy. When recurrences repeat, the possibility of a concomitant autoimmune disease (lupus, rheumatoid arthritis, etc.) is evaluated.
The prognosis of coronary thrombosis not resulting in infarction (I24.0) depends on the extent of underlying coronary artery disease and whether the vessel is recanalized. With complete recanalization and optimal medical therapy, prognosis is favorable, but the risk of recurrence and the likelihood of future myocardial infarction should be evaluated periodically. When vasospasm is the main mechanism, long-term calcium channel blocker therapy can markedly reduce the frequency of attacks, and poor prognostic factors include multivessel spasm, left main spasm, and ventricular arrhythmias during attacks.
Because stunned myocardium is a reversible dysfunction occurring without myocardial necrosis, full functional recovery mostly occurs once reperfusion is successfully achieved. The recovery period ranges from hours to days, and in extensive cases may take up to several weeks. Long-term prognosis depends on the degree of progression of coronary artery disease and management of cardiovascular risk factors.
The most effective prevention of Dressler syndrome is minimizing the extent of myocardial injury through prompt reperfusion therapy. The smaller the infarct, the smaller the amount of myocardial autoantigen released into the blood and the weaker the resulting autoimmune response. Optimization of healthcare systems to shorten door-to-balloon time in STEMI patients is important.
Prophylactic use of colchicine is effective in preventing postinfarction pericardial inflammation, including Dressler syndrome. The COLCOT study (2019) showed that colchicine (0.5mg/day) after myocardial infarction reduced ischemic cardiovascular events by 23%, which included a reduction in pericardial events. Perioperative colchicine may be considered to prevent postpericardiotomy syndrome after cardiac surgery.
Continued aspirin administration has a mild anti-inflammatory effect in addition to its antiplatelet effect and may therefore contribute to reducing the occurrence of Dressler syndrome after infarction. Prophylactic use of nonsteroidal anti-inflammatory drugs is not recommended because they may impair ventricular remodeling after infarction. Prophylactic use of corticosteroids is also not recommended.
Smoking cessation is the most important means of preventing vasospastic angina. Smoking is a major risk factor that impairs endothelial function and promotes vasospasm. Long-term calcium channel blocker therapy (amlodipine, diltiazem) prevents vasospastic attacks, and lifestyle modification to avoid triggers such as excessive drinking, cold environments, and excessive sympathetic stimulation is also important.
Dressler W. A post-myocardial-infarction syndrome: preliminary report of a complication resembling idiopathic, recurrent, benign pericarditis. JAMA. 1956;160(16):1379-1383. DOI: 10.1001/jama.1956.02960510005002. PMID: 13306694.
Imazio M, Brucato A, Rovere ME, et al. Contemporary features, risk factors, and prognosis of the post-pericardiotomy syndrome. American Journal of Cardiology. 2011;108(8):1183-1187. DOI: 10.1016/j.amjcard.2011.06.025. PMID: 21855826.
Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases. European Heart Journal. 2015;36(42):2921-2964. DOI: 10.1093/eurheartj/ehv318. PMID: 26320112.
Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation. 2005;112(13):2012-2016. DOI: 10.1161/CIRCULATIONAHA.105.542738. PMID: 16186437.
Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. New England Journal of Medicine. 2020;383(19):1838-1847. DOI: 10.1056/NEJMoa2021372. PMID: 32865380.
Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. New England Journal of Medicine. 2019;381(26):2497-2505. DOI: 10.1056/NEJMoa1912388. PMID: 31733140.
Bossone E, Enar RJ, Gallotta G, et al. Variant angina: updated clinical and pathophysiological concepts. European Heart Journal. 2023;44(5):374-389. DOI: 10.1093/eurheartj/ehac695. PMID: 36524530.
Braunwald E, Kloner RA. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation. 1982;66(6):1146-1149. DOI: 10.1161/01.cir.66.6.1146. PMID: 6754130.
Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). European Heart Journal. 2019;40(3):237-269. DOI: 10.1093/eurheartj/ehy462. PMID: 30165617.
Imazio M, Gaita F, LeWinter M. Evaluation and treatment of pericarditis: a systematic review. JAMA. 2015;314(14):1498-1506. DOI: 10.1001/jama.2015.12763. PMID: 26461998.